NA Sarcopenia Treatment Market - Industry Trends and Forecast to 2034

Description

List of Tables

The North America sarcopenia treatment market is expected to reach USD 1,814,892.90 thousand by 2030 from USD 1,235,920.05 thousand in 2022, growing at a CAGR of 5.0% in the forecast period of 2023 to 2030.

Market Segmentation

North America Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico,) - Industry Trends and Forecast to 2030.

Overview of North America Sarcopenia Treatment Market Dynamics

Driver
Rising prevalence of sarcopenia
Restraint
Lack of standardized diagnosis
Opportunity
Strategic initiatives by key market players

Market Players

Some of the key market players operating in the North America sarcopenia treatment market are listed below:

Abbott
Nestle Health Science (A subsidiary of Nestle S.A.)
Novartis AG
Sanofi
Haleon Group of Companies
BASF SE
DSM
Fermenta Biotech Limited
AstaReal Co., Ltd.
Metagenics
BioThrive Sciences
Wellona Pharma
The Vitamin Company India
Healing Pharma India Pvt. Ltd
Others

1 INTRODUCTION 17

1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET 17
1.4 CURRENCY AND PRICING 19
1.5 LIMITATIONS 19
1.6 MARKETS COVERED 19

2 MARKET SEGMENTATION 22

2.1 MARKETS COVERED 22
2.2 GEOGRAPHICAL SCOPE 23
2.3 YEARS CONSIDERED FOR THE STUDY 24
2.4 DBMR TRIPOD DATA VALIDATION MODEL 25
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.6 MULTIVARIATE MODELLING 29
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 29
2.8 MARKET END USER COVERAGE GRID 30
2.9 DBMR MARKET POSITION GRID 31
2.10 VENDOR SHARE ANALYSIS 33
2.11 SECONDARY SOURCES 34
2.12 ASSUMPTIONS 34

3 EXECUTIVE SUMMARY 35

4 PREMIUM INSIGHTS 38

4.1 PESTEL ANALYSIS 39
4.2 PORTER'S FIVE FORCES MODEL 40
4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 41

5 NORTH AMERICA SARCOPENIA TREATMENT MARKET: REGULATIONS 42

5.1 REGULATIONS IN U.S. 42
5.2 REGULATIONS IN EUROPE 42
5.3 REGULATIONS IN AUSTRALIA 43
5.4 REGULATIONS IN SOUTH AFRICA 43

6 MARKET OVERVIEW 44

6.1 DRIVERS 46
- 6.1.1 RISING PREVALENCE OF SARCOPENIA 46
- 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 46
- 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 47
6.2 RESTRAINTS 48
- 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 48
- 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 48
6.3 OPPORTUNITIES 49
- 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 49
- 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 49
6.4 CHALLENGES 50
- 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 50
- 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 51

7 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 52

7.1 OVERVIEW 53
7.2 VITAMIN/DIETARY SUPPLEMENTS 56
- 7.2.1 VITAMIN SUPPLEMENTS 57
- 7.2.2 PROTEIN SUPPLEMENTS 57
- 7.2.3 FATTY ACID SUPPLEMENTS 57
- 7.2.4 CREATINE 57
- 7.2.5 WHEY PROTEINS 57
- 7.2.6 L-CARNITINE 57
- 7.2.7 SOY 57
- 7.2.8 BETA-ALANINE 57
- 7.2.9 OSTARINE 57
- 7.2.10 COLLAGEN PEPTIDES 57
- 7.2.11 LIGANDROL 58
- 7.2.12 BRANCH-CHAIN AMINO ACIDS 58
- 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 58
- 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 58
- 7.2.15 OTHERS 58
7.3 MEDICATIONS 58
- 7.3.1 OFF LABEL DRUGS 59
- 7.3.2 EMERGING DRUGS 59
  - 7.3.2.1 ACE INHIBITORS 59
  - 7.3.2.2 APPETITE STIMULANTS 59
  - 7.3.2.3 ORAL ANTIDIABETIC DRUGS 59
  - 7.3.2.4 OTHERS 60
7.4 OTHERS 60

8 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE 61

8.1 OVERVIEW 62
8.2 PRIMARY SARCOPENIA 65
- 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 65
- 8.2.2 MEDICATIONS 65
- 8.2.3 OTHERS 65
8.3 SECONDARY SARCOPENIA 66
- 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 66
- 8.3.2 MEDICATIONS 66
- 8.3.3 OTHERS 66

9 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES 67

9.1 OVERVIEW 68
9.2 PRE-SARCOPENIA 71
9.3 SARCOPENIA 71
9.4 SEVERE SARCOPENIA 72

10 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 73

10.1 OVERVIEW 74
10.2 ORAL 77
10.3 INJECTABLES 77
10.4 OTHERS 78

11 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER 79

11.1 OVERVIEW 80
11.2 MALE 83
11.3 FEMALE 83

12 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER 84

12.1 OVERVIEW 85
12.2 HOSPITALS 88
- 12.2.1 PUBLIC 88
- 12.2.2 PRIVATE 88
12.3 SPECIALTY CLINICS 89
12.4 HOME HEALTHCARE 89
12.5 OTHERS 90

13 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 91

13.1 OVERVIEW 92
13.2 DIRECT TENDER 95
13.3 RETAIL SALES 95
- 13.3.1 HOSPITAL PHARMACIES 96
- 13.3.2 ONLINE PHARMACIES 96
- 13.3.3 OTHERS 96
13.4 OTHERS 96

14 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY REGION 97

14.1 NORTH AMERICA 101
- 14.1.1 U.S. 107
- 14.1.2 CANADA 113
- 14.1.3 MEXICO 119

15 NORTH AMERICA SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 125

15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 125

16 SWOT ANALYSIS 126

17 COMPANY PROFILE 127

17.1 ABBOTT 127
- 17.1.1 COMPANY SNAPSHOT 127
- 17.1.2 REVENUE ANALYSIS 127
- 17.1.3 COMPANY SHARE ANALYSIS 128
- 17.1.4 PRODUCT PORTFOLIO 128
- 17.1.5 RECENT DEVELOPMENT 128
17.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.) 129
- 17.2.1 COMPANY SNAPSHOT 129
- 17.2.2 REVENUE ANALYSIS 129
- 17.2.3 COMPANY SHARE ANALYSIS 130
- 17.2.4 PRODUCT PORTFOLIO 130
- 17.2.5 RECENT DEVELOPMENT 130
17.3 NOVARTIS AG 131
- 17.3.1 COMPANY SNAPSHOT 131
- 17.3.2 REVENUE ANALYSIS 131
- 17.3.3 COMPANY SHARE ANALYSIS 132
- 17.3.4 PRODUCT PORTFOLIO 132
- 17.3.5 PIPELINE PORTFOLIO 132
- 17.3.6 RECENT DEVELOPMENT 132
17.4 SANOFI 133
- 17.4.1 COMPANY SNAPSHOT 133
- 17.4.2 REVENUE ANALYSIS 133
- 17.4.3 COMPANY SHARE ANALYSIS 134
- 17.4.4 PRODUCT PORTFOLIO 134
- 17.4.5 RECENT DEVELOPMENT 134
17.5 HALEON GROUP OF COMPANIES. 135
- 17.5.1 COMPANY SNAPSHOT 135
- 17.5.2 REVENUE ANALYSIS 135
- 17.5.3 COMPANY SHARE ANALYSIS 136
- 17.5.4 PRODUCT PORTFOLIO 136
- 17.5.5 RECENT DEVELOPMENT 136
17.6 ASTAREAL CO., LTD. 137
- 17.6.1 COMPANY SNAPSHOT 137
- 17.6.2 PRODUCT PORTFOLIO 137
- 17.6.3 RECENT DEVELOPMENT 137
17.7 BASF SE 138
- 17.7.1 COMPANY SNAPSHOT 138
- 17.7.2 REVENUE ANALYSIS 138
- 17.7.3 PRODUCT PORTFOLIO 139
- 17.7.4 RECENT DEVELOPMENT 139
17.8 BIOGEN SA 140
- 17.8.1 COMPANY SNAPSHOT 140
- 17.8.2 PRODUCT PORTFOLIO 140
- 17.8.3 RECENT DEVELOPMENT 140
17.9 BIOTHRIVE SCIENCES 141
- 17.9.1 COMPANY SNAPSHOT 141
- 17.9.2 PRODUCT PORTFOLIO 141
- 17.9.3 RECENT DEVELOPMENT 141
17.10 DSM 142
- 17.10.1 COMPANY SNAPSHOT 142
- 17.10.2 REVENUE ANALYSIS 142
- 17.10.3 PRODUCT PORTFOLIO 143
- 17.10.4 RECENT DEVELOPMENT 143
17.11 FERMENTA BIOTECH LIMITED 144
- 17.11.1 COMPANY SNAPSHOT 144
- 17.11.2 REVENUE ANALYSIS 144
- 17.11.3 PRODUCT PORTFOLIO 145
- 17.11.4 RECENT DEVELOPMENT 145

17.12 HEALING PHARMA INDIA PVT. LTD. 146
- 17.12.1 COMPANY SNAPSHOT 146
- 17.12.2 PRODUCT PORTFOLIO 146
- 17.12.3 RECENT DEVELOPMENT 146
17.13 METAGENICS 147
- 17.13.1 COMPANY SNAPSHOT 147
- 17.13.2 PRODUCT PORTFOLIO 147
- 17.13.3 RECENT DEVELOPMENT 147
17.14 THE VITAMIN COMPANY INDIA 148
- 17.14.1 COMPANY SNAPSHOT 148
- 17.14.2 PRODUCT PORTFOLIO 148
- 17.14.3 RECENT DEVELOPMENT 148
17.15 WELLONA PHARMA 149
- 17.15.1 COMPANY SNAPSHOT 149
- 17.15.2 PRODUCT PORTFOLIO 149
- 17.15.3 RECENT DEVELOPMENT 149
17.16 ARMGO PHARMA, INC. 150
- 17.16.1 COMPANY SNAPSHOT 150
- 17.16.2 PIPELINE PORTFOLIO 150
- 17.16.3 RECENT DEVELOPMENT 150
17.17 BIOPHYTIS 151
- 17.17.1 COMPANY SNAPSHOT 151
- 17.17.2 PIPELINE PORTFOLIO 151
- 17.17.3 RECENT DEVELOPMENT 151
17.18 DYSTROGEN THERAPEUTICS CORP 152
- 17.18.1 COMPANY SNAPSHOT 152
- 17.18.2 PIPELINE PORTFOLIO 152
- 17.18.3 RECENT DEVELOPMENT 152
17.19 IMMUNOFORGE INC. 153
- 17.19.1 COMPANY SNAPSHOT 153
- 17.19.2 PIPELINE PORTFOLIO 153
- 17.19.3 RECENT DEVELOPMENT 153
17.20 MYMD PHARMACEUTICALS 154
- 17.20.1 COMPANY SNAPSHOT 154
- 17.20.2 PIPELINE PORTFOLIO 154
- 17.20.3 RECENT DEVELOPMENT 154
17.21 NMD PHARMA A/S 155
- 17.21.1 COMPANY SNAPSHOT 155
- 17.21.2 PIPELINE PORTFOLIO 155
- 17.21.3 RECENT DEVELOPMENT 155
17.22 ONCOCROSS CO., LTD. 156
- 17.22.1 COMPANY SNAPSHOT 156
- 17.22.2 PIPELINE PORTFOLIO 156
- 17.22.3 RECENT DEVELOPMENT 156
17.23 OPKO HEALTH, INC. 157
- 17.23.1 COMPANY SNAPSHOT 157
- 17.23.2 REVENUE ANALYSIS 157
- 17.23.3 PIPELINE PORTFOLIO 158
- 17.23.4 RECENT DEVELOPMENT 158
17.24 REGENERON PHARMACEUTICALS INC. 159
- 17.24.1 COMPANY SNAPSHOT 159
- 17.24.2 REVENUE ANALYSIS 159
- 17.24.3 PIPELINE PORTFOLIO 160
- 17.24.4 RECENT DEVELOPMENT 160
17.25 REJUVENATE BIOMED NV 161
- 17.25.1 COMPANY SNAPSHOT 161
- 17.25.2 PIPELINE PORTFOLIO 161
- 17.25.3 RECENT DEVELOPMENT 161

18 QUESTIONNAIRE 162

19 RELATED REPORTS 166

LIST OF TABLES

TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT 41
TABLE 2 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 55
TABLE 3 NORTH AMERICA VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 56
TABLE 4 NORTH AMERICA VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 56
TABLE 5 NORTH AMERICA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 58
TABLE 6 NORTH AMERICA MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 59
TABLE 7 NORTH AMERICA OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 59
TABLE 8 NORTH AMERICA OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 9 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 64
TABLE 10 NORTH AMERICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 65
TABLE 11 NORTH AMERICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 65
TABLE 12 NORTH AMERICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 13 NORTH AMERICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 14 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 70
TABLE 15 NORTH AMERICA PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 71
TABLE 16 NORTH AMERICA SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 71
TABLE 17 NORTH AMERICA SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 72
TABLE 18 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 76
TABLE 19 NORTH AMERICA ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 20 NORTH AMERICA INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 21 NORTH AMERICA OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 22 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 82
TABLE 23 NORTH AMERICA MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 24 NORTH AMERICA FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 25 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 87
TABLE 26 NORTH AMERICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 27 NORTH AMERICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 88
TABLE 28 NORTH AMERICA SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 29 NORTH AMERICA HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 30 NORTH AMERICA OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 90
TABLE 31 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 94
TABLE 32 NORTH AMERICA DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 33 NORTH AMERICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 34 NORTH AMERICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 96
TABLE 35 NORTH AMERICA OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
TABLE 36 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 37 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 101
TABLE 38 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 39 NORTH AMERICA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 101
TABLE 40 NORTH AMERICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 41 NORTH AMERICA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 102
TABLE 42 NORTH AMERICA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 43 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 44 NORTH AMERICA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 45 NORTH AMERICA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 46 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 104
TABLE 47 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
TABLE 48 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 105
TABLE 49 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
TABLE 50 NORTH AMERICA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 51 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 106
TABLE 52 NORTH AMERICA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 106
TABLE 53 U.S. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 54 U.S. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 55 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 56 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 108
TABLE 57 U.S. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 108
TABLE 58 U.S. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 59 U.S. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 109
TABLE 60 U.S. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 61 U.S. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 62 U.S. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 110
TABLE 63 U.S. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 111
TABLE 64 U.S. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 111
TABLE 65 U.S. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 111
TABLE 66 U.S. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 112
TABLE 67 U.S. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 68 U.S. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 69 CANADA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 70 CANADA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 71 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 113
TABLE 72 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 114
TABLE 73 CANADA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 114
TABLE 74 CANADA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 75 CANADA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 76 CANADA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 77 CANADA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 116
TABLE 78 CANADA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 116
TABLE 79 CANADA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 117
TABLE 80 CANADA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 117
TABLE 81 CANADA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
TABLE 82 CANADA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 83 CANADA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
TABLE 84 CANADA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
TABLE 85 MEXICO SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 86 MEXICO MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 87 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 88 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 120
TABLE 89 MEXICO OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 120
TABLE 90 MEXICO VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 91 MEXICO SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 92 MEXICO PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 93 MEXICO SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 94 MEXICO SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 122
TABLE 95 MEXICO SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 123
TABLE 96 MEXICO SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 123
TABLE 97 MEXICO SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 123
TABLE 98 MEXICO HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
TABLE 99 MEXICO SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124
TABLE 100 MEXICO RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124

LIST OF FIGURES

FIGURE 1 NORTH AMERICA SARCOPENIA TREATMENT MARKET: SEGMENTATION 22
FIGURE 2 NORTH AMERICA SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION 25
FIGURE 3 NORTH AMERICA SARCOPENIA TREATMENT MARKET: DROC ANALYSIS 26
FIGURE 4 NORTH AMERICA SARCOPENIA TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 27
FIGURE 5 NORTH AMERICA SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 NORTH AMERICA SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 NORTH AMERICA SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID 30
FIGURE 8 NORTH AMERICA SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID 31
FIGURE 9 NORTH AMERICA SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS 33
FIGURE 10 NORTH AMERICA SARCOPENIA TREATMENT MARKET: SEGMENTATION 37
FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030 38
FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PRECLINICAL MARKET IN 2023 AND 2030 38
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET 45
FIGURE 14 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022 53
FIGURE 15 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 54
FIGURE 16 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 54
FIGURE 17 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 55
FIGURE 18 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, 2022 62
FIGURE 19 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 63
FIGURE 20 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 63
FIGURE 21 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE 64
FIGURE 22 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, 2022 68
FIGURE 23 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND) 69
FIGURE 24 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030) 69
FIGURE 25 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE 70
FIGURE 26 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 74
FIGURE 27 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 75
FIGURE 28 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 75
FIGURE 29 NORTH AMERICA SARCOPENIA TREATMENT MARKET: LIFELINE CURVE 76
FIGURE 30 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, 2022 80
FIGURE 31 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 81
FIGURE 32 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030) 81
FIGURE 33 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE 82
FIGURE 34 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, 2022 85
FIGURE 35 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 86
FIGURE 36 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030) 86
FIGURE 37 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE 87
FIGURE 38 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 92
FIGURE 39 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 93
FIGURE 40 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 93
FIGURE 41 NORTH AMERICA SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 94
FIGURE 42 NORTH AMERICA SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022) 98
FIGURE 43 NORTH AMERICA SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%) 125